Trial Profile

A Double-blind, Randomized, Placebo-controlled, Phase 1 Safety and Tolerability, and Pharmacokinetics Study of ANAVEX3-71

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ANAVEX3-71 (Primary)
Indications Alzheimer's disease; Dementia; Frontotemporal dementia; Parkinson's disease
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Anavex Life Sciences

24 Jan 2024 According to an Anavex Life Sciences Media Release, company announced a peer-reviewed publication in Clinical Pharmacology in Drug Development findings from the ANAVEX3-71 trial.
24 Jan 2024 Results presented in an Anavex Life Sciences Media Release.
07 Aug 2023 According to an Anavex Life Sciences media release, the company announced a peer-reviewed publication in Clinical Pharmacology in Drug Development, findings from the ANAVEX3-71 first-in-human study which achieved its cardiovascular safety objectives.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com